Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolomics of Dapagliflozin in T2DM
NCT03919656Phase 4Completed
- Start
- May 2019
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Dapagliflozin with Placebo (2 arms). Primary endpoints: Metabolomics changes in blood at 12 weeks and Metabolomics changes in urine at 12 weeks. Started May 2019; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03919656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03919656.